Skip to content

Sarepta Therapeutics, Inc. SRPT Equity Method Investments

Equity Method Investments at other companies

Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$193.49M+30.3%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$61.53M-52.0%

Other financials

Income statement

See full
Revenue$730.8M-1.9%
Operating income-$300.4M-961%
Net income$331.0M+174%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+31.7%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.76B-63.1%

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin4.6%+2.4pp
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-23.6%-28.5pp
Debt / equity0.1×0.0×
Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermInvestments.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s equity method investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s equity method investments?
Sarepta Therapeutics, Inc. (SRPT) reported equity method investments of $81.94M in Q1 2026.
How has Sarepta Therapeutics, Inc.'s equity method investments changed year-over-year?
Sarepta Therapeutics, Inc.'s equity method investments decreased by 24.9% year-over-year, from $109.13M to $81.94M.
What does equity method investments mean?
Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.